rss
Ann Rheum Dis 1998;57:38-41 doi:10.1136/ard.57.1.38
  • Concise reports

Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate

  1. Nicolino Rupertoa,
  2. Angelo Ravellib,
  3. Fernanda Falcinic,
  4. Loredana Lepored,
  5. Rosetta De Sanctise,
  6. Francesco Zulianf,
  7. Antonella Buoncompagnig,
  8. Maria Luisa Sardellah,
  9. Ciro Stranoi,
  10. Maria Alessioj,
  11. Stefania Violab,
  12. Alberto Martini for the Italian Pediatric Rheumatology Study Groupb
  1. aLaboratorio di Informatica Medica, IRCCS S Matteo, Pavia, Italy, bClinica Pediatrica, IRCCS S Matteo, Pavia, Italy, cClinica Pediatrica, Ospedale Meyer, Florence, Italy, dClinica Pediatrica, Istituto Burlo Garofalo, Trieste, Italy, eOspedale Bambin Gesù, Rome, Italy, fClinica Pediatrica, Padova, Italy, gII Divisione di Pediatria, Istituto Gaslini, Genova, Italy, hClinica Pediatrica, Università, Turin, Italy, iClinica Pediatrica, Naples, Italy, jII Divisione di Pediatria, Naples, Italy
  1. Dr A Martini, Clinica Pediatrica, Università di Pavia, IRCCS Policlinico S Matteo, P le Golgi 2, 27100 Pavia, Italy.
  • Accepted 27 October 1997

Abstract

OBJECTIVE To investigate the performance of the core set of outcome measures and the preliminary definition of improvement (PDI) in the assessment of response to methotrexate (MTX) treatment in children with juvenile chronic arthritis (JCA).

METHODS Data were obtained from an open label, non-controlled trial designed to investigate the efficacy of MTX in children with JCA. All patients had the core set of variables assessed at baseline and after six months of treatment. Variables in the core set are: (1) physician global assessment of disease activity; (2) parent or patient (if appropriate in age) global assessment of overall well being; (3) functional ability; (4) number of joints with active arthritis; (5) number of joints with limited range of motion; (6) erythrocyte sedimentation rate. The PDI specifies that to be classified as improved, a patient must show at least 30% improvement from baseline in three of any six variables in the core set, with no more than one of the remaining variables worsening by more than 30%.

RESULTS A total of 111 JCA patients were included in the study. According to the PDI, after six months of MTX treatment 73 patients (66%) were classified as improved and 38 (34%) as not improved. Among the core set variables, parent assessment detected the highest percentage of patients improved (72%) and functional assessment the lowest (37%).

CONCLUSION The PDI identifies about two thirds of patients with JCA treated with low dose MTX as improved. This proportion is similar to that expected to improve based upon a previous controlled study of low dose, oral MTX and provides preliminary evidence of the definition’s validity.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.